This is an expanded access designed to provide access to apixaban for eligibleparticipants.
Drug: Apixaban
Administered as directed by treating physician
Other Name: Eliquis
Inclusion Criteria:
- Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic
Anticoagulation for Thromboembolism Prevention
- Previously participated in the CV185-362 study and was on apixaban for 1 year or
until treatment was no longer required
Exclusion Criteria:
- Weight less than 5 kg or greater than 35 kg
Other inclusion/exclusion criteria apply
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, United States
Investigator: Andrew Glatz, Site 0001
Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Bristol-Myers Squibb, Study Director
Bristol-Myers Squibb